Pages that link to "Item:Q6627253"
From MaRDI portal
The following pages link to A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies (Q6627253):
Displaying 7 items.
- TITE-gBOIN-ET: time-to-event generalized Bayesian optimal interval design to accelerate dose-finding accounting for ordinal graded efficacy and toxicity outcomes (Q6572287) (← links)
- DROID: dose-ranging approach to optimizing dose in oncology drug development (Q6589229) (← links)
- REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors (Q6618357) (← links)
- uTPI: a utility-based toxicity probability interval design for phase I/II dose-finding trials (Q6627822) (← links)
- A Bayesian adaptive phase i/II platform trial design for pediatric immunotherapy trials (Q6627894) (← links)
- TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy (Q6628336) (← links)
- Commentary on: ``Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies'' (Q6629386) (← links)
